Provides cancer testing and expert interpretation for medical practices, hospitals and laboratories, and pharmaceutical companies.
10-K for FY2025, filed Feb 17, 2026
Clinical tests are billed to clients and health insurers after results reach the ordering physician; pharmaceutical and biotech clients and other research groups are billed for completed service units, with some contracts including upfront fees as work proceeds. Data is licensed as retrospective records upon delivery or as prospective feeds over time.
10-K for FY2025, filed Feb 17, 2026The Company’s specialized clinical services are performed based on a written test requisition form or electronic equivalent. The…View ↗
For the Company's pharmaceutical development services, the Company generally enters into contracts with pharmaceutical and biotech clients…View ↗
Additional offerings within the Company's portfolio includes oncology data solutions, which involves the licensing of de-identified data to…View ↗
10-K for FY2025, filed Feb 17, 2026
FY2025 revenue by product or service ↗$727.3M
10-K for FY2025, filed Feb 17, 2026
$727.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Client direct billing
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
71%
FY2022: 73%
|
Client direct billing, FY2025
$518.8M Sources
|
Sold outright |
|
Commercial insurance
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
16%
FY2022: 14%
|
Commercial insurance, FY2025
$117.5M Sources
|
Sold outright |
|
Medicare and other government
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
12%
FY2022: 13%
|
Medicare and other government, FY2025
$90.9M Sources
|
Sold outright |
|
Self-pay
Sold outright
|
<0.1%
FY2022: <0.1%
|
Self-pay, FY2025
$114K Sources
|
Sold outright |
Community pathology and oncology practices, hospitals and academic centers use cancer testing and interpretation services; pharmaceutical firms buy research testing and data services. The company’s sales and business-development teams work directly with clinical clients and sponsors.
10-K for FY2025, filed Feb 17, 2026We operate under a single segment that encompasses a comprehensive range of services. This approach aims to streamline our operations and…View ↗
Our specialized pharmaceutical development services support pharmaceutical firms (“sponsors”) through the provision of laboratory testing…View ↗
These services provide comprehensive support in oncology programs, including biomarker discovery, study design, and clinical trial testing.…View ↗
Our direct sales force has been trained extensively in cancer genetic testing and consultative selling skills to service the needs of…View ↗
The Company operates under a single segment based on an analysis of the Company's reporting structure, the information available to the…View ↗
No. It lost $108M in FY2025.
10-Q for Q3 FY2026, filed Oct 28, 2026
−$7.5MView ↗
10-Q for Q3 FY2026, filed Oct 28, 2026
Open tableView ↗
8-K, filed Jul 28, 2026
FY 2025 Previous FY 2026 Guidance UpdatedFY 2026 Guidance YOY % Change from FY 2025 (in millions) Actual Low High Low High Low High…View ↗
Growing. Revenue grew 50% in 4 years, from $484.3M in FY2021 to $727.3M in FY2025, about 11% a year.
Oncology data licensing
The older report described expanding informatics and data tools to help stakeholders identify trial patients and support decisions; the latest report describes licensed de-identified records and prospective data feeds as oncology data solutions.
10-K for FY2022, filed Feb 24, 2023 10-K for FY2025, filed Feb 17, 2026We are committed to connecting patients with life-altering therapies and trials. In carrying out these commitments, we aim to provide…View ↗
Competes with Quest Diagnostics, Laboratory Corporation of America, ARUP, Guardant Health, Natera, Exact Sciences, Caris Life Science, Tempus AI, and Myriad Genetics
10-K for FY2025, filed Feb 17, 2026Our competitors within the broader genomics profiling space include laboratory companies such as Quest Diagnostics, Laboratory Corporation…View ↗
Loading...